Correlation of margin status and extraprostatic extension with progression of prostate carcinoma

Cancer

Volumn 86, Issue 9, 1999, Pages 1775-1782

  Cheng, Liang ^a   Darson, Michael F ^b   Bergstralh, Erik J ^b   Slezak, Jeff ^b   Myers, Robert P ^b   Bostwick, David G ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c BOSTWICK LABORATORIES   (United States)

Author keywords

DNA ploidy; Extraprostatic extension; Margins; Neoplasms; Progression; Prostate; Prostate specific antigen; Prostatectomy; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PLOIDY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RISK FACTOR; SURGICAL TECHNIQUE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLOIDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0033229741     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991101)86:9<1775::AID-CNCR20>3.0.CO;2-L     Document Type: Article

References (35)

1. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276:615-9.
2. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995;154: 1447-52.
3. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994:152:1850-7.
4. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160: 299-315.
5. Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodrigue R, Henson DE, et al. Staging and reporting of prostate cancer: sampling of the radical prostatectomy specimen. Cancer 1996;78:366-8.
6. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma. What are the issues? Cancer 1996;78:337-40.
7. Bostwick DG. Staging prostate cancer, 1997: current methods and limitations. Eur Urol 1997;32:2-14.
8. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol 1994;10:60-72.
9. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997;28:143-8.
10. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al. AJCC cancer staging manual. Philadelphia: Lippincott-Raven, 1997.
11. Bostwick DG. Neoplasms of the prostate. In: Bostwick DG, Eble JN, editors. Urologic surgical pathology. 1st edition. St. Louis: Mosby, 1997:343-422.
12. Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, et al. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer 1998;82:902-8.
13. Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 1997;50:733-9.
14. van den Ouden D, Hop WC, Kranse R, Schroder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997;79:203-11.
15. Fesseha T, Sakr W, Grignon D, Banerjee M, Wood DP Jr., Pontes JE. Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol 1997;158:2176-9.
16. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.
17. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
18. Catalona WJ, Stein AJ. Staging errors in clinically localized protate cancer. J Urol 1982;127:452-6.
19. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomic radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-42.
20. Montie JE. Staging of prostate cancer. Cancer 1995;75: 1814-8.
21. Lowe BA, Lieberman SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997;158: 1452-6.
22. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.
23. Jones D, Hafermann MD, Rieke JW, Vermeulen SS. An estimate of the margin required when defining blocks around the prostate. Br J Radiol 1995;68:740-6.
24. Paulson DF, Stone AR, Walther PJ, Tucker JA, Cox EB. Radical prostatectomy: anatomical predictors of success or failure. J Urol 1986;136:1041-3.
25. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144:1180-4.
26. Smith RC, Partin AW, Epstein JI, Brendler CB. Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 1996;156:454-8.
27. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996;48:80-90.
28. Weldon VE, Tavel FR, Neuwirth H, Cohen R. Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. J Urol 1995; 153:1565-9.
29. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
30. Eisbrush A, Perez CA, E.H. R, Lockett MA. Adjuvant irradiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer 1994;73:384-7.
31. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996; 47:232-5.
32. Hudson MA, Catalona WJ. Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol 1990;143:1174-7.
33. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment of disease outcome. Urology 1993;42: 283-91.
34. Mayer FJ, Crawford ED. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am 1994;21:707-15.
35. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996;29:425-33.